UBS Group
EVMN

UBS Group’s Evommune Inc EVMN Stock Holding History

UBS Group’s Portfolio EVMN Stock Details EVMN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$6.86M Buy
298,375
+294,961
+8,640% +$6.67M ﹤0.01% 3742
2025
Q4 		$58.4K Buy
+3,414
New +$64.1K ﹤0.01% 7146

Other funds holding EVMN

EFM
EQT Fund Management Luxembourg $1.02B AUM
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
PBPIA
Pivotal bioVenture Partners Investment Advisor San Francisco, California $280M AUM 181.4% 1-Year Est. Return
AP
Andera Partners Paris $206M AUM
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
NFGH
Nan Fung Group Holdings Kai Tak, Hong Kong $121M AUM 56.89% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
SCP
SymBiosis Capital Partners Bentonville, Arkansas $52.8M AUM
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

UBS Group's EVMN Position: Q1 2026 in Review

UBS Group increased its Evommune Inc (EVMN) stake by 8,640% in Q1 2026, buying an estimated $6.67M and bringing the position to 298,375 shares worth $6.86M. The position accounts for ﹤0.01% of the portfolio, ranked #3742.

UBS Group first reported a position in EVMN in Q4 2025 and has held it in 2 quarters since. 84 funds tracked by Wall St. Rank hold EVMN as of Q1 2026.

  • UBS Group held 298,375 shares of Evommune Inc worth $6.86M as of Q1 2026.
  • UBS Group bought 294,961 Evommune Inc shares in Q1 2026, an estimated $6.67M.
  • Evommune Inc made up ﹤0.01% of UBS Group's portfolio in Q1 2026, its #3742 holding.
  • UBS Group first reported a position in Evommune Inc in Q4 2025 and has held it in 2 quarters since.
  • 84 funds tracked by Wall St. Rank held Evommune Inc as of Q1 2026.

Based on UBS Group's 13F filing for Q1 2026, filed 5 May 2026.